Vytorin/Zetia Drug Marketing
Result: $41.5 million settlement
Year: 2010
In re Vytorin/Zetia Marketing, Sales Practices & Products Liability Litigation
Lieff Cabraser served on the Executive Committee of Plaintiffs’ Steering Committee in multidistrict litigation arising out of the sale and marketing of Vytorin and Zetia, two cholesterol drugs marketed and sold by Merck/Schering-Plough Pharmaceuticals, a joint venture between Merck & Co., Inc. and Schering-Plough Corp.
Plaintiffs alleged that Vytorin and Zetia were marketed as being more effective than other anti-cholesterol drugs and were sold at higher prices when they were no more effective than less expensive anti-cholesterol drugs.
On February 9, 2010, the Court granted final approval to a $41.5 million settlement for persons and entities which paid for these drugs between November 2002 and the date of final approval of the settlement.
Civil Litigation News
Mark Chalos Selected as Co-Lead Counsel for Plaintiffs in Generac Solar Power Systems Marketing Practice and Products Liability Litigation
The Generac Solar Energy Systems litigation focuses on allegations that energy tech giant Generac’s PWRECell System components are defective and potentially dangerous
Sarah London Testifies Before the CA State Assembly in Support of Bill to Stop Corporate Arbitration Abuse in California
On June 13, 2023, Lieff Cabraser partner Sarah London testified before the California State Assembly in support of SB 365. The bill,
Lieff Cabraser Announces Historic $235M Comprehensive Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Cases
Unprecedented in scope, speed, and significance, the global settlement, reached just after plaintiffs concluded their case in the bellwether trial in San
